Skip Nav Destination
Issues
1 April 2020
-
Cover Image
Cover Image
In this issue of Molecular Cancer Therapeutics, we present the first two examples of the new "First Disclosures" article type. This article type is designed to highlight the first-time disclosure of oncology drug structures and their preclinical profiles. The cover image, taken from our large molecule example, demonstrates the proposed complex structure of the variable region of the CD137 agonist 7A5 (in red cartoon) with CD137 (in white). The CD137L binding site is also shown in blue. Read the full disclosure of the 7A5 antibody on page 988. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
MCT First Disclosures
Author Choice
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian; Patrice Lee; Janelle Taylor; Robert Rosler; Peter de Vries; Daniel Watson; Andres Forero-Torres; Scott Peterson
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Helen Kotanides; Rose Marie Sattler; Maria B. Lebron; Carmine Carpenito; Juqun Shen; Jingxing Li; David Surguladze; Jaafar N. Haidar; Colleen Burns; Leyi Shen; Ivan Inigo; Anthony L. Pennello; Amelie Forest; Xinlei Chen; Darin Chin; Andreas Sonyi; Michael Topper; Lauren Boucher; Prachi Sharma; Yiwei Zhang; Douglas Burtrum; Ruslan D. Novosiadly; Dale L. Ludwig; Gregory D. Plowman; Michael Kalos
Review
Small Molecule Therapeutics
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance
Marco H. Hofmann; Rajeswaran Mani; Harald Engelhardt; Maria A. Impagnatiello; Sebastian Carotta; Marc Kerenyi; Seila Lorenzo-Herrero; Jark Böttcher; Dirk Scharn; Heribert Arnhof; Andreas Zoephel; Renate Schnitzer; Thomas Gerstberger; Michael P. Sanderson; Girish Rajgolikar; Swagata Goswami; Sumithira Vasu; Peter Ettmayer; Segundo Gonzalez; Mark Pearson; Darryl B. McConnell; Norbert Kraut; Natarajan Muthusamy; Jürgen Moll
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Sophie Piperno-Neumann; James Larkin; Richard D. Carvajal; Jason J. Luke; Gary K. Schwartz; F. Stephen Hodi; Marie-Paule Sablin; Alexander N. Shoushtari; Sebastian Szpakowski; Niladri Roy Chowdhury; A. Rose Brannon; Thiruvamoor Ramkumar; Leanne de Koning; Adnan Derti; Caroline Emery; Padmaja Yerramilli-Rao; Ellen Kapiteijn
Large Molecule Therapeutics
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
Sun K. Ho; Zhenghai Xu; Archana Thakur; Melvin Fox; Siu Sze Tan; Enrico DiGiammarino; Li Zhou; Mien Sho; Belinda Cairns; Vivian Zhao; Mengli Xiong; Josue Samayoa; Charles M. Forsyth; David B. Powers; Debra T. Chao; Diane Hollenbaugh; Hamsell M. Alvarez; Yoshiko Akamatsu
Author Choice
Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies
Lidia Nazarova; Hanine Rafidi; Danielle Mandikian; Gregory Z. Ferl; James T. Koerber; Christopher W. Davies; Sheila Ulufatu; Jason Ho; Jeffrey Lau; Shang-Fan Yu; James Ernst; Jack D. Sadowsky; C. Andrew Boswell
Author Choice
Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models
Ulrike Weyer-Czernilofsky; Marco H. Hofmann; Katrin Friedbichler; Rosa Baumgartinger; Paul J. Adam; Flavio Solca; Norbert Kraut; Holly M. Nguyen; Eva Corey; Gang Liu; Cynthia C. Sprenger; Stephen R. Plymate; Thomas Bogenrieder
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy
Maike Zimmermann; Tao Li; Thomas J. Semrad; Chun-Yi Wu; Aiming Yu; George Cimino; Michael Malfatti; Kurt Haack; Kenneth W. Turteltaub; Chong-xian Pan; May Cho; Edward J. Kim; Paul T. Henderson
Models and Technologies
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.